Please use this identifier to cite or link to this item:
|Title:||How to Control the United States Pharmaceutical API Market Using Patents on New Synthetic Intermediate Compounds|
|Keywords:||ANDA;Pharmaceutical patent;Drug patent;Pharmaceutical economics;Synthetic intermediate|
|Abstract:||The multinational pharmaceutical industry now out-sources a much higher volume of active pharmaceutical ingredients from manufacturers in non-regulated markets such as Brazil, India and China. This economic change presents an opportunity for API manufacturers to potentially control the market in the United States for certain APIs, by capitalizing on a particular provision of US patent law. This paper reviews this law, examines several actual case studies under this law, and provides a check list of characteristics useful to identify the most valuable Active Pharmaceutical Ingredients (API) manufacturing opportunities.|
|Appears in Collections:||JIPR Vol.13(5) [September 2008]|
Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.